Policy Statement NORD provides comments in support of the FDA’s Patient Focused Drug Development Listening Meeting ‘Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products’
News NORD Applauds Advancement of Critical Legislation Encouraging Rare Disease Drug Development and Improving Access to Care; Urges Continued Bipartisanship to Help People Living with Rare Diseases
News NORD Appoints Genetics and Metabolic Specialist Marshall L. Summar M.D. as Chairman of the Board
Policy Statement NORD’s Statement in Support for Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
